Abstract

BackgroundAnti-tumour necrosis factor (anti-TNF) therapy has been widely used for refractory rheumatoid arthritis (RA) and psoriatic arthritis (PsA) over the past 10 years. Safety data from randomised controlled trials (RCTs)...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Tumor Necrosis Factor-α Blockade and Development of Uveal Melanoma: Expected Adverse Effect or Just Coincidence?
Takami Sato
Mayo Clinic Proceedings | VOL. 89
Takami SatoTakami Sato
01 Nov 2014
German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - Part 2: Treatment monitoring and specific clinical or comorbid situations.
Tobias Weberschock ... Ralph Von Kiedrowski
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG | VOL. 19
Tobias Weberschock, et. al.Tobias Weberschock ... Ralph Von Kiedrowski
01 Jul 2021
Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden
Johan Askling ... Pauline Raaschou
BMJ | VOL. 352
Johan Askling, et. al.Johan Askling ... Pauline Raaschou
28 Jan 2016
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review
Charles N Bernstein ... Geoffrey C Nguyen
Gastroenterology | VOL. 160
Charles N Bernstein, et. al.Charles N Bernstein ... Geoffrey C Nguyen
01 Oct 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers